Novo Nordisk (NYSE: NVO) reports 24,959,179 shares repurchased in 2026 programme

Rhea-AI Filing Summary

Novo Nordisk A/S reports progress on its B-share repurchase programme conducted under EU Safe Harbour Rules. The company expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026, including a sub-programme of up to DKK 11,200,000,010.45 running from 6 May 2026 to 1 February 2027.

Following purchases between 13 and 17 July 2026, accumulated repurchases under the 6 May programme reached 10,200,000 B shares for DKK 3,053,177,399. Since 4 February 2026, Novo Nordisk has repurchased 24,959,179 B shares at an average price of DKK 274.58, for a total of DKK 6,853,177,389. The company now holds 42,144,480 B shares as treasury shares, equal to 0.9% of its 4,465,000,000 A and B shares outstanding, and its B shares are listed on Nasdaq Copenhagen with ADRs on the NYSE.

Key Figures

Overall buyback programme: DKK 15 billion Sub-programme cap: DKK 11,200,000,010.45 Shares under 6 May programme: 10,200,000 B shares +4 more

7 metrics

Overall buyback programme DKK 15 billion Expected B-share repurchases during 12-month period beginning 4 February 2026

Sub-programme cap DKK 11,200,000,010.45 Maximum B-share repurchases from 6 May 2026 to 1 February 2027

Shares under 6 May programme 10,200,000 B shares Accumulated repurchases under the programme as of 17 July 2026; value DKK 3,053,177,399

Shares repurchased since 4 Feb 2026 24,959,179 B shares Total B shares repurchased from 4 February 2026 to 17 July 2026; value DKK 6,853,177,389

Average repurchase price DKK 274.58 per B share Average price of B shares repurchased between 4 February and 17 July 2026

Treasury shares held 42,144,480 B shares Treasury B shares corresponding to 0.9% of share capital

Total share capital 4,465,000,000 shares Total A and B shares in the company including treasury shares

Key Terms

share repurchase programme, treasury shares, Safe Harbour Rules, Regulation No 596/2014, +2 more

6 terms

share repurchase programme financial

"initiated a share repurchase programme in accordance with Article 5"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

treasury shares financial

"owns a total of 42,144,480 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

Safe Harbour Rules regulatory

"2016/1052 of 8 March 2016 (the "Safe Harbour Rules")"

Regulation No 596/2014 regulatory

"in accordance with Article 5 of Regulation No 596/2014 of the European Parliament"

Commission Delegated Regulation (EU) 2016/1052 regulatory

"and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016"

ADRs financial

"Its ADRs are listed on the New York Stock Exchange (NVO)"

American Depositary Receipts (ADRs) are certificates issued by a U.S. bank that stand in for shares of a foreign company, allowing those shares to be bought and sold on U.S. stock exchanges in U.S. dollars. Think of an ADR as a local ticket representing a foreign stock: it makes trading, settlement, and tax reporting simpler for U.S. investors, but still exposes them to risks like currency moves, different accounting rules, and foreign corporate practices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/21/2026 - 06:04 AM Accepted by SEC EDGAR 07/21/2026 - 06:01 AM Learn about SEC filing dates

FAQ

What is the size and duration of Novo Nordisk (NVO) 2026 share repurchase programme?

Novo Nordisk plans to repurchase B shares for up to DKK 15 billion over a 12-month period beginning 4 February 2026. This overall programme includes a sub-programme launched on 6 May 2026, capped at DKK 11,200,000,010.45 and running until 1 February 2027.

How many shares has Novo Nordisk (NVO) repurchased so far in 2026?

As of 17 July 2026, Novo Nordisk has repurchased 24,959,179 B shares since 4 February 2026. These repurchases were made at an average price of DKK 274.58 per B share, for a total transaction value of DKK 6,853,177,389.

What were Novo Nordisk (NVO) share buybacks in the latest reported week?

Between 13 and 17 July 2026, Novo Nordisk bought 195,000 B shares on each trading day. After these purchases, accumulated repurchases under the 6 May 2026 programme reached 10,200,000 B shares, corresponding to a transaction value of DKK 3,053,177,399.

How many treasury shares does Novo Nordisk (NVO) currently hold?

Novo Nordisk now holds 42,144,480 B shares of DKK 0.10 as treasury shares, representing 0.9% of its share capital. The total number of A and B shares in the company, including treasury shares, is 4,465,000,000.

Under which regulations is the Novo Nordisk (NVO) buyback conducted?

The repurchase of B shares is carried out under Article 5 of Regulation No 596/2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, referred to as the Safe Harbour Rules governing market-abuse-safe buyback practices in the European Union.

Where are Novo Nordisk (NVO) shares and ADRs traded?

Novo Nordisk’s B shares are listed on Nasdaq Copenhagen under Novo-B. Its American Depositary Receipts (ADRs) are listed on the New York Stock Exchange under the symbol NVO, providing access for U.S. investors.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

July 20, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 20 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 13 July 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	9,225,000		2,734,545,468
13 July 2026	195,000	322.69	62,923,858
14 July 2026	195,000	320.55	62,507,407
15 July 2026	195,000	323.83	63,147,108
16 July 2026	195,000	333.59	65,050,395
17 July 2026	195,000	333.35	65,003,163
Accumulated under the programme	10,200,000		3,053,177,399

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 42,144,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 17 July 2026, Novo Nordisk has since 4 February 2026 repurchased a total 24,959,179 B shares at an average share price of DKK 274.58 per B share equal to a transaction value of DKK 6,853,177,389.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown +45 3079 9289 globalmedia@novonordisk.com	Liz Skrbkova (US) +1 609 917 0632 USMediaRelations@novonordisk.com
Investors:
Michael Novod +45 3075 6050 nvno@novonordisk.com	Sina Meyer +45 3079 6656 azey@novonordisk.com
Max Ung +45 3077 6414 mxun@novonordisk.com	Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com
Alex Bruce +45 3444 2613 axeu@novonordisk.com	Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com	Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 43 / 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: July 20, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer